Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial
- Department of Radiation Oncology, Washington University, St. Louis, MO (United States)
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC (United States)
- Clinic of Radiation Oncology, University of Freiburg, Freiburg (Germany)
- Medical Oncology and Radiotherapy at the Centre Hospitalier Andre-Boulloche, Montbeliard (France)
- Department of Radiotherapy, Institute Gustave-Roussy, Villejuif Cedex (France)
- Department of Radiation Oncology, University of Erlangen, Erlangen (Germany)
Purpose: To evaluate chronic xerostomia and tumor control 18 and 24 months after initial treatment with amifostine in a randomized controlled trial of patients with head-and-neck cancer; at 12 months after radiotherapy (RT), amifostine had been shown to reduce xerostomia without changing tumor control. Methods and Materials: Adults with head-and-neck cancer who underwent once-daily RT for 5-7 weeks (total dose, 50-70 Gy) received either open-label amifostine (200 mg/m{sup 2} i.v.) 15-30 min before each fraction of radiation (n = 150) or RT alone (control; n = 153). Results: Amifostine administration was associated with a reduced incidence of Grade {>=}2 xerostomia over 2 years of follow-up (p = 0.002), an increase in the proportion of patients with meaningful (>0.1 g) unstimulated saliva production at 24 months (p = 0.011), and reduced mouth dryness scores on a patient benefit questionnaire at 24 months (p < 0.001). Locoregional control rate, progression-free survival, and overall survival were not significantly different between the amifostine group and the control group. Conclusions: Amifostine administration during head-and-neck RT reduces the severity and duration of xerostomia 2 years after treatment and does not seem to compromise locoregional control rates, progression-free survival, or overall survival.
- OSTI ID:
- 20706238
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 63, Issue 4; Other Information: DOI: 10.1016/j.ijrobp.2005.07.966; PII: S0360-3016(05)02215-7; Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Reducing Xerostomia After Chemo-IMRT for Head-and-Neck Cancer: Beyond Sparing the Parotid Glands
A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer